International Journal of Drug Delivery Technology
Volume 15, Issue 1

Nanosized Drug Loaded Dispersion System Using Novel Isolated Biomaterial as Drug Release Modifier. It’s Development, Characterization and Release study

Sushant Kumar1, Yogesh Chand Yadav1*, Sanjay K Kannaujia2, Mudit Kumar1, Sanjay Kumar1

1Faculty of Pharmacy, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, 206130, U.P. India

2Department of Pathology, Faculty of Medicine, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, 206130, UP, India 

Received: 8th Jan, 2025; Revised: 26th Feb, 2025; Accepted: 11th Mar, 2025; Available Online: 25th Mar, 2025 

ABSTRACT

Epilepsy is a chronic brain illness that manifests as seizures, which are episodes of abnormal electrical activity in the brain. This study aimed to create the model drug-PHT-loaded bionanodispersion, reduce the long-term treatment expenses for epilepsy, and enhance therapeutic efficacy by utilizing the novel bioretardant from Juglans regia (JR). In order to create a nanocapsulated dispersion system, a new bioretardant with exceptional inherent characteristics was extracted. For the planning of details PLBND1 through PLBND5, various ratios of the bioretardant and the model drug, PHT, were used: 1:2, 1:3, 1:4, 1:5, and 1:8. Dispersibility, pH, % entrapment efficiency, stability studies, and in vitro drug discharge were evaluated for the bionanodispersion. With a t50% of 17.21 hours and an estimated r2 of 0.9974, the formulation PLBND2 with a 1:4 drug bioretardant proportion demonstrated noteworthy results for a number of evaluations. In 36 hours, PLBND2 demonstrated a steady drug delivery rate of 93.17% ± 1.8. Using a bioretardant with a remarkable stabilizing and retardant property, the bionanodispersion was proven to be safe and stable for the administration of the nanosized model drug, PHT.

Keywords: Edible seeds, Bioretardant, Biomatrial,  Nanosizing, Bionanodispersion, Epilepsy

How to cite this article: Sushant Kumar, Yogesh Chand Yadav, Sanjay K Kannaujia, Mudit Kumar, Sanjay Kumar. Nanosized model drug loaded nanoparticulate dispersion system using novel isolated bioretardant as a drug release retardant cum stabilizer: It’s Development, Characterization and In-vitro release study. International Journal of Drug Delivery Technology, 2025;15(1):146-53. doi: 10.25258/ijddt.15.1.20

REFERENCES

  1. Kreutzer J. Nanoparticles in Colloidal Drug Delivery Systems, New York; Marcel Dekker Inc: 9nd:, 1994; 23
  2. Madhav NVS, Yadav AP. Development and evaluation of novel repaglinide biostrips for translabial delivery.International Research Journal of Pharmacy. 2013;4:198-202
  3. Ojha A. and Madhav, NVS. A novel potent mucobioadhesant polymer from seeds of Ricinuscommunis.World Journal of Pharmaceutical Sciences. 2014; 3: 2154-2165.
  4. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002 Apr;43(4):365-85.
  5. Zhang J. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. International Journal of Pharmaceutics. 2006; 323: 153-63.
  6. Dawood NM. Formulation and characterization of lafutidine nanosuspension for oral drug delivery system. International Journal of Applied Pharmaceutics. 2018; 10:20-30
  7. Madhav NVS, Singh B. A smart approach for delivering of nanosized olanzapine using piper betel bioretardant rate controlling flexi films for transvermillion delivery. Asian Journal of Nanoscience and Materials. 2019; 2: 314-326.
  8. Moschwitzer J, Achleitner G,   Pomper H. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. European Journal of Pharmaceutics and Biopharmaceutics. 2004; 58 : 615–619.
  9. Muller RH, Jacobs C, Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Advanced Drug Delivery Reviews. 2001 Mar 23;47(1):3-19..
  10. Madhav NVS, Shankar MSU. A novel smart mucoadhesive biomaterial from Lallimantiaroyalena seed coat. Science Asia. 2011; 37: 69–71.
  11. Hecq J, Siepmann F, Amighi K, Goole J. Development and evaluation of chitosan and chitosan derivative nanoparticles containing insulin for oral administration. Drug Development and Industrial Pharmacy. 2015;  41, 2037-2044.
  12. Bennewitz MF, Saltzman WM. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics. 2009; 6(2):323-36.
  13. Tyagi Y, Madhav NVS. Smart innovative approach for designing fluvoxamine loaded bio-nanosuspension for the management of depression.Journal of Applied Pharmaceutical Science 2019; 11: 191-197.
  14. Tyagi Y, Madhav NVS. Design selegiline loaded bio-nanosuspension for the management of depression using novel bio-retardent from Manilkarazapota. Drug Development and Industrial Pharmacy. 2019; 45:1351-1360.
  15. Rosenblatt KM, Bunjes H. Evaluation of the drug loading capacity of different lipid nanoparticle dispersions by passive drug loading. European Journal of Pharmaceutics and Biopharmaceutics. 2017 Aug;117:49-59. doi: 10.1016/j.ejpb.2017.03.010. Epub 2017 Mar 16. PMID: 28315731.
  16. Jethara SI, Patel AD, Patel MR, Patel MS, Patel KR. Recent survey on nanosuspension: a patent overview. Recent Pat Drug Deliv Formul. 2015;9(1):65-78. doi: 10.2174/1872211308666141028214003. PMID: 25354346.
  17. Shen J, Burgess DJ. In Vitro Dissolution Testing Strategies for Nanoparticulate Drug Delivery Systems: Recent Developments and Challenges. Drug Deliv Transl Res. 2013 Oct 1;3(5):409-415. doi: 10.1007/s13346-013-0129-z. PMID: 24069580.
  18. Madhav NVS, Raina D. Formulation and performance evaluation of Escitalopram loaded bionanodispersionusing a novel bio-retardant from Piper nigrum. International Journal of Life Sciences.  2017;5:60–66.
  19. Bennewitz MF, Saltzman WM. Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics. 2009 Apr;6(2):323-36. doi: 10.1016/j.nurt.2009.01.018.